Biomarker Translation & Development
This structured R&D programme undertakes research & development on biomarker-based diagnostic assays, targeting oncology, inflammatory, autoimmune, infectious disease and inherited disease areas.
The programme, adopts a ‘portfolio model’ towards biomarker characterisation, linking the genomic biomarker and clinical histories data which its research produces, to data in relevant external datasets, thus building a novel and comprehensive clinical and genomics knowledge base.
The programme will then, through Artificial Intelligence enabled data mining, identify novel biomarkers with industrial potential. As well as accessing candidate biomarkers from leading global academic and Pharma sources, the programme will create a strong research partnership with The University of Manchester and the Manchester Foundation Trust, who undertakes a complementary fundamental research on elements of the programme.
Biomarkers emerging successfully from the programme will be available for sale to the corporate market for subsequent experimental product development.
Biomarker Development Pipeline - 2024
Current Areas of Interest:
Breast Cancer prognostic, predictive and subtyping signatures
Leukaemia (including AML)
Apoptosis regulation in Cancer within the p53 family
Diagnostic applications of long noncoding RNAs in cancer and other diseases
Early detection of liver fibrosis and liver cancer
Lung Disease: Cancer, COPD, Asthma, ARDS (including COVID-19)
Infectious disease detection and immunoserology, including SARS-CoV-2
Antibiotic Resistance Markers
Sepsis
